SGX Pharmaceuticals - Best Pharma Stocks of 2007

Company: SGX Pharmaceuticals
Starting stock price: $3.314
Ending stock price: $4.76
Percent Change: 43.81%

Details: SGX is focused on developing cancer drugs, and uses its FAST technology to identify and optimize small molecule fragments that bind to specific targets. In 2007 SGX filed an IND for SGX523 for solid tumors. The company also has a number of preclinical programs for relapsed/refractory chronic myelogenous leukemia (CML) and front-line CML.

More News:
SGX Initiates Phase I Trials for SGX523. Report
SGX shares tank on late-stage trial failure. Report

SGX Pharmaceuticals - Best Pharma Stocks of 2007

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.